About Avisi

Our Story

Avisi Technologies was founded in 2017 through the University of Pennsylvania Y-Prize program. At the time, Avisi’s founders dreamed of applying novel nanotechnologies to combat vision loss and prevent blindness. Through interdisciplinary efforts across materials science engineering and ophthalmology, the VisiPlate technology was born. With initial support from the President’s Innovation Prize, National Science Foundation SBIR grants, MedTech Innovator, and more, Avisi accelerated its growth significantly.

Today, Avisi’s diverse and expert team remains committed to our mission to restore health and promote vitality. Together we’ll create a world with accessible, cutting-edge healthcare solutions for all.

Leadership

Rui Jing Jiang

Founder, CEO, and Director

LinkedIn

Jeff Emery, PhD

Senior VP of R&D and Operations

LinkedIn

Georgia Griggs, MSE

Principal Engineer, Site Head

LinkedIn

Kim Du, CCRP

Senior Director of Clinical Operations

LinkedIn

Catherine Mohr, MD, MSME

Director of the Board

LinkedIn

Gary Pruden

Director of the Board

LinkedIn

Paul Norris, JD

Director of the Board

LinkedIn

Brandon Kao

Founder and Director

LinkedIn

Scientific Advisory Board

Eydie Miller-Ellis, MD

Director of the Glaucoma Fellowship Program at Scheie Eye Institute and Professor of Clinical Ophthalmology at University of Pennsylvania

Website

Richard A. Lewis, MD

Former Director of Glaucoma at the University of California, Davis, past President of ASCRS, past President of American Glaucoma Society, and Co- Founder, Sacramento Eye Consultants

Website

Iqbal (Ike) K. Ahmed, MD, FRCSC

Head of Ophthalmology at Trillium Health Partners, Chief Innovation Officer at Prism Eye Institute, Professor of Ophthalmology at University of Utah and John Moran Eye Center

Website

Ehsan Sadri, MD, FACS, FAAO

Founder and CEO of Visionary Eye Institute, Founding Board Member of Visionary Ventures Fund.

Website

Vance Thompson, MD

President of ASCRS, Director of Refractive Surgery at Vance Thompson Vision, Professor of Ophthalmology at Sanford USD School of Medicine

Website

Jonathan S. Myers, MD

Director of Wills Eye Hospital Glaucoma Service and Professor, Sidney Kimmel Medical College at Thomas Jefferson University

Website

Vivian Lee, MD

Co-director of the William C. Frayer Ophthalmic Pathology Laboratory and Assistant Professor of Ophthalmology at the Hospital of the University of Pennsylvania

Website

Georges Durr, MD, FRCSC

Surgeon at CHUM, Associate Clinical Professor at the University of Montreal

Website
Joseph F. Panarelli, MD Avisi Technologies As an ophthalmologist at NYU Langone, I have the unique opportunity to work with a diverse patient population because I manage glaucoma in adults and children. Through these experiences, I’m able to build long-term relationships with patients, which I find extremely rewarding. I chose to specialize in glaucoma because it allows me to provide ongoing medical care and surgical treatments to patients to improve their quality of life. Through clinical and academic opportunities in the specialty of glaucoma, I can offer meaningful patient care. During my clinical training and my early academic career, most of my research focused on the surgical management of glaucoma. I have published about several new surgical techniques as well as new findings comparing traditional glaucoma procedures to current ones. I have also been part of numerous clinical trials for new surgical devices for eye procedures. Joseph F. Panarelli, MD

Joseph F. Panarelli, MD

Director of Glaucoma Services, NYU Langone Health and Professor of Ophthalmology at NYU Grossman School of Medicine

Website

Barry Cheskin, MS, MBA

President & CEO and Co-Founder, Powervision (acq. Alcon)

LinkedIn

Samuel Nicaise, PhD

Electrical engineering and microscale materials expert

LinkedIn

Join Our Team: Shape the Future of Healthcare

Avisi’s mission is to restore health and promote vitality. We envision creating a world with accessible, cutting-edge healthcare solutions for everyone.

As part of our team, you will be at the forefront of developing the next-generation treatment for glaucoma, the world’s leading cause of irreversible blindness.

  • For information on full-time position openings, you can follow our LinkedIn where we post openings.
  • Interns at Avisi have the opportunity to work on 1-2 projects over an 8-10 week period.
  • We are always happy to meet students who have an interest in MedTech innovation. Interns gain the most when they have already completed at least 2 years of undergraduate coursework and research.

 

For full-time employment and internship opportunities feel free to reach out to info@avisitech.com.

Avisi team

Supporting Our Vision: Partners in Progress

Avisi is supported by a network of venture investors, esteemed universities, the National Science Foundation (NSF), and industry groups like AdvaMed Accel. Our journey is further highlighted by our membership in Johnson & Johnson’s JLABS incubator and our alumni status with the MedTech Innovator Accelerator and UCSF Rosenman Innovator programs.

If you’re interested in investment opportunities please contact info@avisitech.com.

Transparent globe with insufficient data in a wireframe design on a blue background with reflection below.

Supported by

Accanto Partners Logo
Life Sciences Greenhouse Investments Logo
MedVenture Partners
Mountain State Capital Logo
Skip to content